Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — Investor Presentation (September 2016)
39 slides from Genetic Signatures's investor presentation, Sep 2, 2016
Slide 1: Capital Raising Presentation – September 2016
For personal use only Capital Raising Presentation – September 2016 1
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Genetic Signatures Limited (“GSS”). The information contained in this presentation is for information purposes only and has been prepared for use in conjunction with a verbal presentation and should be read in that context. This
Slide 3: Company Overview
Company Overview For personal use only § Genetic Signatures Limited (GSS) designs and manufactures proprietary molecular diagnostic test solutions for rapid and specific identification of diseases and infections § GSS fully owns its proprietary molecular 3Base™ technology with multiple patents issue
Slide 4: Corporate Summary
Corporate Summary For personal use only Financial Information (A$) Top Shareholders % ASX Code GSS Asia Union Investment Pty Limited 50.6% Shares on Issue 72.7m DAK Drafting Services Pty Ltd 2.7% Market Capitalisation $37.0m UBS Nominees Pty Ltd 2.4% Share Price (at market close 30 August 2016) $0.5
Slide 5: Capital Raising Details
Capital Raising Details For personal use only § Genetic Signatures has raised $14m via a Two Tranche Placement to institutional and sophisticated investors with a Share Purchase Plan to raise a further $1m to follow § The Placement was oversubscribed with strong support from offshore specialist heal
Slide 6: Capital Raising Timetable
Capital Raising Timetable For personal use only Trading halt Wednesday, 31 August 2016 Transac'on announced & Company resumes trading Friday, 2 September 2016 Placement Tranche 1 Se\lement of new shares Wednesday, 7 September 2016 Placement Tranche 1 Allotment of new shares Thursday, 8 September 201
Slide 7: Recent Achievements
Recent Achievements For personal use only 2000 § Strong sales growth, with a 3-year CAGR of Annual Sales Revenue 92% 1800 3yr CAGR of 92% § FY16 revenue of A$1.83M, split ~80% 1600 Gastroenteritis, ~20% Respiratory specialist 1400 sales $Thousands (A$) 1200 § Advancing R&D development of 5 new Respi
Slide 8: Large and Growing Global Molecular Diagnostics Market
Large and Growing Global Molecular Diagnostics Market For personal use only § Molecular Diagnostics (MDx) Market estimated to be US$7.6Bn in 2017 representing 11% of the overall in vitro Diagnostics (IVD) market of $US69.1Bn § MDx market forecast to grow at an above system CAGR of 9.3% far exceeding
Slide 9: Large addressable markets
Large addressable markets For personal use only § Genetic Signatures’ (GSS) current diagnostics products and pipeline products account for >50% of microbiology/virology diagnostics segment, representing what was a total addressable market of $US1.11Bn in 2012 § This segment is estimated to be worth
Slide 10: Regulatory approvals already gained in large portion of US$7.6Bn global market
Regulatory approvals already gained in large portion of For personal use only US$7.6Bn global market - driving revenue § Full regulatory approval for ~22% of the global market in Gastroenteritis testing, with 2017 Es?mate MDx Market Size by Region (USD) partial approval (Clinical Concentrators, Anal
Slide 11: Significant Offshore Opportunity
Significant Offshore Opportunity For personal use only § Strong revenue growth in Australia validates commercial potential of products in offshore markets § Enteric products have full approval in Europe which is 10-20x Australian market § Specialist clinical sales of Enteric ASR tests into N. Americ
Slide 12: Experienced Board and Management
Experienced Board and Management For personal use only Nick Samaras - Non-Executive Chairman BSc (Hons), PhD, MBA, FAIM, FAICD § More than 25 years’ experience in the global life sciences industry, senior executive roles with Applied Biosystems (now part of Thermo Fisher) and Perkin Elmer § NHMRC Re
Slide 13: Experienced Board and Management
Experienced Board and Management For personal use only Tony Radford, AO - Non-Executive Director BSc (Hons), PhD § A member of the CSIRO team that invented the QuantiFERON method for Cellular Immune based diagnostics § Co-founded the diagnostic company Cellestis Limited which listed on the ASX in 20
Slide 14: Genetic Signatures: Transforming Global Molecular Diagnostics
For personal use only Genetic Signatures Transforming Global Molecular Diagnostics 14
Slide 15: Unique 3Base Technology
Unique 3Base™ Technology For personal use only § GSS’ unique platform technology converts original 4-base microbial genome to 3-base, thereby reducing complexity in molecular testing § Applicable in testing for infectious diseases and chronic diseases including cancers § The conversion occurs during
Slide 16: Technology - 3Base
Technology - 3Base™ Massive reduction in complexity For personal use only § § e.g, a 10 digit number comprised of the numbers 1,2,3 and 4 has 1,048,576 combinations § a 10 digit number comprised of the numbers 1,2 and 3 has 59,049 combinations § Reduces complexity by 97% yet maintains or increases a
Slide 17: EasyScreen Testing Kits
EasyScreen™ Testing Kits For personal use only § GSS’ suite of EasyScreen™ products are being adopted by major hospitals & pathology laboratories in Australia for detection of infectious diseases § Products work to deliver a wider array of highly specific results in 4-5 hours that would have traditi
Slide 18: Case Study: St Vincent's Hospital Evaluation Study
Case Study: St Vincent’s Hospital Evaluation Study - Powerful evidence of efficacy For personal use only Pathogen Conventional EasyScreen™ § 221 patient samples compared to Methods* traditional culture, microscopy and Campylobacter 7 9 antibody based tests Salmonella 8 9 Shigella 5 6 § Results in 4
Slide 19: For personal use only
“I find that the fast For personal use only turnaround time and the number of targets tested in the EasyScreen™ assays allow me to more rapidly identify highly infectious agents, potentially stopping the spread to other healthy individuals and thereby saving the health system money.” - Dr Damien Sta
Slide 20: Advantages of 3base Technology
Advantages of 3base™ Technology For personal use only Significant benefits to the health system Pathology Groups / Government Patient Hospitals § Patients receive more § Cost savings due to § Reduce hospital stays accurate test results decreased time spent through more effective § Faster turn around
Slide 21: Global Growth Strategy and Commercial Progress
For personal use only Global Growth Strategy and Commercial Progress 21
Slide 22: Global Growth Strategy
Global Growth Strategy For personal use only § Focus on regions with regulatory approvals § Australia, Europe and US, together account for >80% of world MDx market § Extend footprint in both Europe and US § Europe has unique testing and reimbursement strategies – local knowledge is critical § Full d
Slide 23: Commercialisation Progress - Australia
Commercialisation Progress - Australia For personal use only § Currently in market with major hospital and pathology group customers, including St. Vincent’s Sydney and Australian Clinical Labs § Driving strong revenue growth for Australian sales, 92% 3yr CAGR § FY16 Sales revenue up 75% to AU$1.83M
Slide 24: Commercialisation Progress - Australia (Cont)
Commercialisation Progress - Australia (Cont) For personal use only § Dedicated R&D labs and network of clinical partners driving new product development § 4 EasyScreen™ products for Gastroenteritis have TGA approval § C. difficile detection and reflex kits; Enteric Protozoan & Bacterial Kits § 2 mo
Slide 25: Commercialisation Progress - Europe
Commercialisation Progress - Europe For personal use only § Western European market ~20% of the global molecular diagnostics market § Addressable market of ~US$435M § Targeting first significant recurring revenues in FY17 § Full distributors appointed in Italy, Israel, Poland and Ireland § Currently
Slide 26: Commercialisation Progress - Europe
Commercialisation Progress - Europe For personal use only § 2 more EasyScreen™ kits are being validated for CE-IVD approval § For Respiratory and Enteric Viral infections § European Director, Sales and Support, appointed, based in the Netherlands § Establishing direct Sales and Support in Europe § M
Slide 27: Commercialisation Progress – North America
Commercialisation Progress – North America For personal use only § US market 50-60% of the global molecular diagnostics market § Up to ~US$1,265M addressable market § Anticipate first sales in FY17 § Direct sales and support model with established and experienced US team § Early revenue underpinned
Slide 28: Commercialisation Progress – North America
Commercialisation Progress – North America For personal use only § UCLA evaluation concluded with successful product trial, publication to follow and progressing to adopt into routine use § First products are being prepared for full FDA approval, allowing unrestricted sales in the US § FDA approval
Slide 29: Outlook
Outlook § Significant progress made during FY16 & further strong growth expected in FY17 For personal use only § FY16 sales revenues of AU$1.83M, representing a 3 year CAGR of 92% § Launch of specialist products for sale into Australia and prepared for US § Alliances made with leading KOL and health
Slide 30: Appendix
For personal use only Appendix 30
Slide 31: Comparable companies demanding large valuations
Comparable companies demanding large valuations For personal use only § Comparable companies within the molecular diagnostics field trade on an average revenue multiple of 8.6x § This multiple exists under the spectre of the 3 year CAGR of the three closest comparable companies being an average of 9
Slide 32: Technology - 3Base
Technology - 3Base™ For personal use only A transformational MDx technology enabling customers to identify a wider array of patient infections § Genetic Signatures’ 3Base™ platform is a proprietary molecular technique which changes naturally occurring DNA and RNA sequences to reduce sequence variati
Slide 33: 3base Simplifying Pathology Testing
3base™ Simplifying Pathology Testing For personal use only § Pathology providers strive to Minimise work, Maximise results § Desire to get more results per patient specimen § Thus put more and more primers and probes for more and more diseases in a single tube and sample, to get more answers with le
Slide 34: 3base Simplifying Pathology Testing
3base™ Simplifying Pathology Testing For personal use only More Primers, more Probes, more Problems Conventional PCR - at some point the trade off in problems limits the Interference multiplex capacity with specificity and or sensitivity GSS solution allows more results with less work Primer probe n
Slide 35: 3base Advantages
3base™ Advantages For personal use only GSS is winning market share due to the following: § Unique 3base™ products that screen over 20 pathogens, including RNA and DNA viruses, in a probe based real-time format § No post amplification analysis required § Uses latest technology compatible with existi
Slide 36: Immense US Market Potential
Immense US Market Potential For personal use only § US has 5,686 registered hospitals § Over 900,000 staffed beds § Over 35 million admissions § 11,000 CLIA certified laboratories § 3Base™ Technology offers unique advantages for the US Market § High numbers of pathogens detected delivers desirable p
Slide 37: US Market Trends
US Market Trends For personal use only § Centers for Disease Control and Prevention (CDC) estimates that annually, at least two million illnesses and 23,000 deaths are caused by antibiotic-resistant bacteria in the United States alone § The Infectious Disease Society of America produced a policy pap
Slide 38: US Market Expansion Approach
US Market Expansion Approach For personal use only § Discussions underway with Key Opinion Leaders to trial Genetic Signatures’ technology § Patient outcome studies – define superior patient care through implementation of broad pathogen screening protocols § Head-to-Head comparison between 3Base™ as
Slide 39: Contact
For personal use only Contact: John Melki Chief Executive Officer john@geneticsignatures.com www.geneticsignatures.com 39
Genetic Signatures — Investor Presentation (September 2016) on 6ix